vs
STANDARD BIOTOOLS INC.(LAB)与Orchid Island Capital, Inc.(ORC)财务数据对比。点击上方公司名可切换其他公司
Orchid Island Capital, Inc.的季度营收约是STANDARD BIOTOOLS INC.的2.0倍($38.5M vs $19.6M),Orchid Island Capital, Inc.净利率更高(268.7% vs -177.4%,领先446.1%),Orchid Island Capital, Inc.同比增速更快(372.6% vs -11.5%),过去两年Orchid Island Capital, Inc.的营收复合增速更高(301.6% vs -12.2%)
Standard BioTools(原Fluidigm公司)是一家美国生命科学工具企业,主营流式细胞术与组织成像分析用质谱流式系统,以及配套的检测试剂盒与试剂,同时供应自动化基因组分析仪器、各类微流控芯片(又称集成流体电路)及配套试剂耗材,全系列产品及应用场景均可提供定制检测方案与相关服务。
Orchid Island Capital是一家总部设在美国的专业金融企业,以房地产投资信托的形式开展运营,主要投资机构类及非机构类住宅抵押贷款支持证券,深耕美国固定收益市场,致力于为投资者创造稳定的经风险调整后的长期回报。
LAB vs ORC — 直观对比
营收规模更大
ORC
是对方的2.0倍
$19.6M
营收增速更快
ORC
高出384.1%
-11.5%
净利率更高
ORC
高出446.1%
-177.4%
两年增速更快
ORC
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $19.6M | $38.5M |
| 净利润 | $-34.7M | $103.4M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | — |
| 净利率 | -177.4% | 268.7% |
| 营收同比 | -11.5% | 372.6% |
| 净利润同比 | -28.8% | 1764.9% |
| 每股收益(稀释后) | $-0.09 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
LAB
ORC
| Q4 25 | — | $38.5M | ||
| Q3 25 | $19.6M | $26.9M | ||
| Q2 25 | $21.8M | $23.2M | ||
| Q1 25 | $40.8M | $19.7M | ||
| Q3 24 | $22.1M | $340.0K | ||
| Q2 24 | $22.5M | $-697.0K | ||
| Q1 24 | $45.5M | $-2.5M | ||
| Q4 23 | $28.2M | — |
净利润
LAB
ORC
| Q4 25 | — | $103.4M | ||
| Q3 25 | $-34.7M | $72.1M | ||
| Q2 25 | $-33.5M | $-33.6M | ||
| Q1 25 | $-26.0M | $17.1M | ||
| Q3 24 | $-26.9M | $17.3M | ||
| Q2 24 | $-45.7M | $-5.0M | ||
| Q1 24 | $-32.2M | $19.8M | ||
| Q4 23 | $-19.8M | — |
毛利率
LAB
ORC
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — | ||
| Q4 23 | 47.6% | — |
营业利润率
LAB
ORC
| Q4 25 | — | — | ||
| Q3 25 | -168.5% | — | ||
| Q2 25 | -118.1% | — | ||
| Q1 25 | -80.8% | — | ||
| Q3 24 | -120.9% | — | ||
| Q2 24 | -134.5% | — | ||
| Q1 24 | -132.2% | — | ||
| Q4 23 | -75.9% | — |
净利率
LAB
ORC
| Q4 25 | — | 268.7% | ||
| Q3 25 | -177.4% | 267.8% | ||
| Q2 25 | -153.7% | -145.0% | ||
| Q1 25 | -63.8% | 86.9% | ||
| Q3 24 | -122.0% | 5094.1% | ||
| Q2 24 | -203.3% | 714.3% | ||
| Q1 24 | -70.6% | -794.2% | ||
| Q4 23 | -70.2% | — |
每股收益(稀释后)
LAB
ORC
| Q4 25 | — | — | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.07 | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.12 | — | ||
| Q1 24 | $-0.27 | — | ||
| Q4 23 | $-0.24 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $665.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $1.4B |
| 总资产 | $539.6M | $11.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
LAB
ORC
| Q4 25 | — | $665.9M | ||
| Q3 25 | $129.4M | $583.9M | ||
| Q2 25 | $158.6M | $440.8M | ||
| Q1 25 | $150.9M | $396.4M | ||
| Q3 24 | $210.6M | $322.1M | ||
| Q2 24 | $269.8M | $241.0M | ||
| Q1 24 | $287.1M | $190.4M | ||
| Q4 23 | $51.7M | — |
总债务
LAB
ORC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — | ||
| Q4 23 | $63.5M | — |
股东权益
LAB
ORC
| Q4 25 | — | $1.4B | ||
| Q3 25 | $399.7M | $1.1B | ||
| Q2 25 | $424.5M | $912.0M | ||
| Q1 25 | $454.6M | $855.9M | ||
| Q3 24 | $489.3M | $656.0M | ||
| Q2 24 | $510.3M | $555.9M | ||
| Q1 24 | $577.3M | $481.6M | ||
| Q4 23 | $-148.1M | — |
总资产
LAB
ORC
| Q4 25 | — | $11.7B | ||
| Q3 25 | $539.6M | $9.1B | ||
| Q2 25 | $557.0M | $7.6B | ||
| Q1 25 | $579.6M | $7.3B | ||
| Q3 24 | $681.5M | $5.9B | ||
| Q2 24 | $708.7M | $4.9B | ||
| Q1 24 | $777.7M | $4.2B | ||
| Q4 23 | $323.1M | — |
负债/权益比
LAB
ORC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $120.4M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | 1.16× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势,按日历期对齐
经营现金流
LAB
ORC
| Q4 25 | — | $120.4M | ||
| Q3 25 | $-22.2M | $28.0M | ||
| Q2 25 | $-20.7M | $18.4M | ||
| Q1 25 | $-30.3M | $25.8M | ||
| Q3 24 | $-27.9M | $-14.8M | ||
| Q2 24 | $-39.0M | $19.3M | ||
| Q1 24 | $-62.5M | $45.0M | ||
| Q4 23 | $-14.1M | — |
自由现金流
LAB
ORC
| Q4 25 | — | — | ||
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — | ||
| Q4 23 | $-14.1M | — |
自由现金流率
LAB
ORC
| Q4 25 | — | — | ||
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — | ||
| Q4 23 | -50.2% | — |
资本支出强度
LAB
ORC
| Q4 25 | — | — | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — | ||
| Q4 23 | 0.3% | — |
现金转化率
LAB
ORC
| Q4 25 | — | 1.16× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.51× | ||
| Q3 24 | — | -0.86× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.28× | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
ORC
暂无分部数据